MX2019007377A - Uso de inhibidores de la quimasa para el tratamiento de la endometriosis, la fibrosis postoperatoria y los trastornos que se caracterizan por fibrosis. - Google Patents

Uso de inhibidores de la quimasa para el tratamiento de la endometriosis, la fibrosis postoperatoria y los trastornos que se caracterizan por fibrosis.

Info

Publication number
MX2019007377A
MX2019007377A MX2019007377A MX2019007377A MX2019007377A MX 2019007377 A MX2019007377 A MX 2019007377A MX 2019007377 A MX2019007377 A MX 2019007377A MX 2019007377 A MX2019007377 A MX 2019007377A MX 2019007377 A MX2019007377 A MX 2019007377A
Authority
MX
Mexico
Prior art keywords
fibrosis
treatment
endometriosis
post
diseases
Prior art date
Application number
MX2019007377A
Other languages
English (en)
Inventor
Peters Michaele
Koch Markus
Zollner Thomas
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2019007377A publication Critical patent/MX2019007377A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud se relaciona con el uso de derivados de uracilo sustituido con bicíclicos, solos o en combinaciones con otros ingredientes activos para el tratamiento y/o la profilaxis de enfermedades, en particular para el tratamiento y/o profilaxis de trastornos inflamatorios y fibróticos, para el tratamiento de la endometriosis, de la fibrosis asociada a la endometriosis, de la adenomiosis y del dolor asociado con un trastorno de la endometriosis y también de la fibrosis peritoneal postoperatoria y la formación de adherencias.
MX2019007377A 2016-12-20 2017-12-13 Uso de inhibidores de la quimasa para el tratamiento de la endometriosis, la fibrosis postoperatoria y los trastornos que se caracterizan por fibrosis. MX2019007377A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16205339.1A EP3338780A1 (de) 2016-12-20 2016-12-20 Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
PCT/EP2017/082569 WO2018114514A1 (de) 2016-12-20 2017-12-13 Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind

Publications (1)

Publication Number Publication Date
MX2019007377A true MX2019007377A (es) 2019-09-18

Family

ID=57570813

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007377A MX2019007377A (es) 2016-12-20 2017-12-13 Uso de inhibidores de la quimasa para el tratamiento de la endometriosis, la fibrosis postoperatoria y los trastornos que se caracterizan por fibrosis.

Country Status (19)

Country Link
US (1) US11266646B2 (es)
EP (2) EP3338780A1 (es)
JP (1) JP2020502272A (es)
KR (1) KR20190098984A (es)
CN (1) CN110072527A (es)
AU (1) AU2017381324A1 (es)
BR (1) BR112019012503A2 (es)
CA (1) CA3047448A1 (es)
CL (1) CL2019001713A1 (es)
EA (1) EA201991292A1 (es)
IL (1) IL266823B (es)
JO (1) JOP20190149A1 (es)
MA (1) MA47067A (es)
MX (1) MX2019007377A (es)
PH (1) PH12019501409A1 (es)
SG (1) SG10202106586TA (es)
TW (1) TWI753070B (es)
UA (1) UA124848C2 (es)
WO (1) WO2018114514A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021000933A1 (zh) * 2019-07-03 2021-01-07 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
CN114671856B (zh) * 2020-12-25 2023-10-20 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
WO2022135534A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 取代的含氮双环化合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071220B2 (en) * 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
US20040018984A1 (en) * 2002-07-17 2004-01-29 Mizuo Miyazaki Methods for preventing adhesion formation using protease inhibitors
WO2008045688A1 (en) 2006-10-06 2008-04-17 Boehringer Ingelheim International Gmbh Chymase inhibitors
US9150556B2 (en) * 2007-05-22 2015-10-06 Boehringer Ingelheim International Gmbh Benzimidazolone chymase inhibitors
UA112897C2 (uk) 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
MA39020A1 (fr) 2013-11-08 2017-04-28 Bayer Pharma AG Sels de l'acide 1 -(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluorométhyl)-2,3-dihydro-lh-indén-1 -yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique
US9695131B2 (en) 2013-11-08 2017-07-04 Bayer Pharma Aktiengesellschaft Substituted uracils as chymase inhibitors
CA2929753A1 (en) 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted uracils and use thereof
US20160287599A1 (en) 2013-11-08 2016-10-06 Bayer Pharma Aktiengesellschaft Substituted 1,2,4-triazine-3,5-diones and the use thereof as chymase inhibitors

Also Published As

Publication number Publication date
EP3338780A1 (de) 2018-06-27
KR20190098984A (ko) 2019-08-23
JOP20190149A1 (ar) 2019-06-19
JP2020502272A (ja) 2020-01-23
BR112019012503A2 (pt) 2020-04-14
MA47067A (fr) 2019-10-30
US11266646B2 (en) 2022-03-08
CL2019001713A1 (es) 2019-11-15
US20190381040A1 (en) 2019-12-19
CN110072527A (zh) 2019-07-30
UA124848C2 (uk) 2021-12-01
WO2018114514A1 (de) 2018-06-28
AU2017381324A1 (en) 2019-07-04
PH12019501409A1 (en) 2020-03-09
IL266823B (en) 2022-03-01
CA3047448A1 (en) 2018-06-28
TW201827053A (zh) 2018-08-01
EA201991292A1 (ru) 2019-12-30
EP3558316A1 (de) 2019-10-30
TWI753070B (zh) 2022-01-21
SG10202106586TA (en) 2021-07-29
IL266823A (en) 2019-07-31

Similar Documents

Publication Publication Date Title
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2019011825A (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad de c5a.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
MX2017014199A (es) Composiciones de nanoparticulas para terapia sostenida.
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
PH12019501409A1 (en) Use of chymase inhibitors for the treatment of endometriosis, post-operative fibrosis and diseases which are characterized by fibrosis formation
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
WO2015168532A3 (en) Compositions and methods for modulating pkk expression
MX2020006587A (es) Derivados de aminopiridina como inhibidores de fosfatidilinositol fosfato cinasa.
EA201790802A1 (ru) Соединения против tnf
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
MX2020006614A (es) Derivados de cromenopiridina como inhibidores de fosfatidilinositol fosfato cinasa,.
NZ713080A (en) Pyridin-4-yl derivatives
EA201892714A1 (ru) Имидазолиновые соединения в качестве ингибиторов эластазы нейтрофилов человека
MX2015017035A (es) Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.
EA201791294A1 (ru) 7-(МОРФОЛИНИЛ)-2-(N-ПИПЕРАЗИНИЛ)МЕТИЛТИЕНО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
BR112017018183A2 (pt) derivados de pirimidina como inibidores de quinase e suas aplicações terapêuticas.
EP3452047A4 (en) COMPOSITIONS FOR THE TREATMENT OF CHRONIC VULVA AND COLUMN PAIN AND SYMPTOMS AND ASSOCIATED therewith